<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33902051</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0208</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>3</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Neuroepidemiology</Title><ISOAbbreviation>Neuroepidemiology</ISOAbbreviation></Journal><ArticleTitle>The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016-2018: The Ohio Population-Based ALS Registry.</ArticleTitle><Pagination><StartPage>196</StartPage><EndPage>205</EndPage><MedlinePgn>196-205</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000515103</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is a fatal, neuromuscular disease with no cure. ALS incidence rates have not been assessed specifically in Ohio, yet the state contains both metropolitan and rural areas with a variety of environmental factors that could contribute to disease etiology. We report the incidence of ALS in Ohio residents diagnosed from October 2016 through September 2018.</AbstractText><AbstractText Label="METHODS">We engaged practitioners from 9 Ohio sites to identify newly diagnosed ALS patients and to complete case report forms with demographic and clinical information. ALS was diagnosed according to the Awaji criteria and classified as either definite, probable, or possible. We developed a method to estimate missing cases using a Poisson regression model to impute cases in counties with evidence of undercounting.</AbstractText><AbstractText Label="RESULTS">We identified 333 newly diagnosed ALS patients residing in Ohio during the 2-year index period and found incidence rates varied in the 88 state counties. After incorporating the estimated 27% of missing cases, the corrected crude annual incidence was 1.96/100,000 person-years, and the age- and gender-standardized incidence was 1.71/100,000 person-years (standardized to the 2010 US census).</AbstractText><AbstractText Label="DISCUSSION/CONCLUSION">The estimated Ohio incidence of ALS is overall similar to that reported in other states in the USA. This study reveals a geospatial variation in incidence within the state, and areas with higher rates warrant future investigation.</AbstractText><CopyrightInformation>The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andrew</LastName><ForeName>Angeline S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Section of ALS and Related Disorders, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meifang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Geography, Dartmouth College, Hanover, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Geography, Dartmouth College, Hanover, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gui</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stommel</LastName><ForeName>Elijah W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Tanya H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peipert</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henegan</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tischbein</LastName><ForeName>Maeve</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cazzolli</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ALS Care Project, Canton, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ohio Health Physician Group, Westerville, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quick</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugar</LastName><ForeName>K Doug</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Dayton Center for Neurological Disorders, Dayton, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawlani</LastName><ForeName>Komal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katirji</LastName><ForeName>Bashar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Todd A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Riverhills Neuroscience, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention (CDC), Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention (CDC), Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Walter G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000245</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuroepidemiology</MedlineTA><NlmUniqueID>8218700</NlmUniqueID><ISSNLinking>0251-5350</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009820" MajorTopicYN="N" Type="Geographic">Ohio</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Hot spots</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Ohio</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>26</Day><Hour>20</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33902051</ArticleId><ArticleId IdType="pmc">PMC8220927</ArticleId><ArticleId IdType="doi">10.1159/000515103</ArticleId><ArticleId IdType="pii">000515103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009 Feb 24;72((8)):725&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">19237701</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018 Jan;17((1)):94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015 Feb 12;7:181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblond CS, Kaneb HM, Dion PA, Rouleau GA. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol. 2014 Dec;262 Pt B:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">24780888</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014 Jan;17((1)):17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangi G, Traynor BJ. Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 2015 May 14;1607:75&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5916786</ArticleId><ArticleId IdType="pubmed">25316630</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang SY, Teo KC, Hsu JS, Chang RS, Li M, Sham PC, et al. The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: a review. Transl Neurodegener. 2017 Oct 6;6:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639582</ArticleId><ArticleId IdType="pubmed">29046784</ArticleId></ArticleIdList></Reference><Reference><Citation>Taskesen E, Mishra A, van der Sluis S, Ferrari R, Veldink JH, van Es MA, et al. Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with amyotrophic lateral sclerosis by DNA-methylation and GWAS. Sci Rep. 2017 Aug 21;7((1)):8899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567187</ArticleId><ArticleId IdType="pubmed">28827549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, Andrew AS, Traynor BJ, Chi&#xf2; A, Butt TH, Stommel EW. Gene-environment-time interactions in neurodegenerative diseases: hypotheses and research approaches. Ann Neurosci. 2018 Dec;25((4)):261&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470336</ArticleId><ArticleId IdType="pubmed">31000966</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014 Nov;13((11)):1108&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, D'Alfonso S, Corrado L, Canosa A, Moglia C, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology. 2018 Aug 14;91((7)):e635&#x2013;e42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis: United States, 2010&#x2013;2011. MMWR Suppl. 2014 Jul 25;63((7)):1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25054277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan H, Fagliano J, Rechtman L, Lefkowitz D, Kaye W. Population-based surveillance of amyotrophic lateral sclerosis in New Jersey, 2009&#x2013;2011. Neuroepidemiology. 2014;43((1)):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552177</ArticleId><ArticleId IdType="pubmed">25323440</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Motor Neuron Disease Collaborators Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Dec;17((12)):1083&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology. 2009 May 12;72((19)):1640&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433736</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017 Feb;46((1)):57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis: United States, 2015. MMWR Morb Mortal Wkly Rep. 2018 Nov 23;67((46)):1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner L, Rechtman L, Jordan H, Ritsick M, Sanchez M, Sorenson E, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17((1&#x2013;2)):128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4732418</ArticleId><ArticleId IdType="pubmed">26399278</ArticleId></ArticleIdList></Reference><Reference><Citation>Caller TA, Doolin JW, Haney JF, Murby AJ, West KG, Farrar HE, et al. A cluster of amyotrophic lateral sclerosis in New Hampshire: a possible role for toxic cyanobacteria blooms. Amyotroph Lateral Scler. 2009;10((Suppl 2)):101&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19929741</ArticleId></ArticleIdList></Reference><Reference><Citation>Caller TA, Field NC, Chipman JW, Shi X, Harris BT, Stommel EW. Spatial clustering of amyotrophic lateral sclerosis and the potential role of BMAA. Amyotroph Lateral Scler. 2012 Jan;13((1)):25&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">22214351</ArticleId></ArticleIdList></Reference><Reference><Citation>Caller TA, Chipman JW, Field NC, Stommel EW. Spatial analysis of amyotrophic lateral sclerosis in Northern New England, USA, 1997&#x2013;2009. Muscle Nerve. 2013 Aug;48((2)):235&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23881670</ArticleId></ArticleIdList></Reference><Reference><Citation>Masseret E, Banack S, Boum&#xe9;di&#xe8;ne F, Abadie E, Brient L, Pernet F, et al. Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from Southern France. PLoS One. 2013;8((12)):e83406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3862759</ArticleId><ArticleId IdType="pubmed">24349504</ArticleId></ArticleIdList></Reference><Reference><Citation>Torbick N, Hession S, Stommel E, Caller T. Mapping amyotrophic lateral sclerosis lake risk factors across northern New England. Int J Health Geogr. 2014 Jan;13:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922844</ArticleId><ArticleId IdType="pubmed">24383521</ArticleId></ArticleIdList></Reference><Reference><Citation>Torbick N, Ziniti B, Stommel E, Linder E, Andrew A, Caller T, et al. Assessing cyanobacterial harmful algal blooms as risk factors for amyotrophic lateral sclerosis. Neurotox Res. 2018 Jan;33((1)):199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727154</ArticleId><ArticleId IdType="pubmed">28470570</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012 Nov;69((11)):1410&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohio Department of Health [Internet].  Population data for calculating rates [cited 2020 July 30]  Available from:  http://publicapps.odh.ohio.gov/EDW/DataBrowser/Browse/Population.</Citation></Reference><Reference><Citation>United States Census Bureau [Internet]  2010 census data products: United States.  [cited 2020 July 30] Available from:  https://www.census.gov/population/www/cen2010/glance/</Citation></Reference><Reference><Citation>Ohio 2018 BRFSS Annual Report Chronic disease epidemiology and evaluation section, office of health improvement and wellness, Ohio department of health. 2020</Citation></Reference><Reference><Citation>Preux PM, Druet-Cabanac M, Couratier P, Debrock C, Truong T, Marcharia W, et al. Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. J Clin Epidemiol. 2000 Oct;53((10)):1025&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11027935</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, Topol B, Kaye W, Williamson D, Horton DK, Mehta P, et al. Estimation of the prevalence of amyotrophic lateral sclerosis in the United States using national administrative healthcare data from 2002 to 2004 and capture-recapture methodology. Neuroepidemiology. 2018;51((3&#x2013;4)):149&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250049</ArticleId><ArticleId IdType="pubmed">30092573</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267((4)):944&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Freer C, Hylton T, Jordan HM, Kaye WE, Singh S, Huang Y. Results of Florida's amyotrophic lateral sclerosis surveillance project, 2009&#x2013;2011. BMJ Open. 2015 Apr 21;5((4)):e007359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410133</ArticleId><ArticleId IdType="pubmed">25900464</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention [Internet]  State-metro ALS surveillance.  [cited 2020 July 30] Available from:  https://www.cdc.gov/als/ALSStateMetro.html.</Citation></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Wu R, Larson T, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis: United States, 2014. MMWR Morb Mortal Wkly Rep. 2018 Feb 23;67((7)):216&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858037</ArticleId><ArticleId IdType="pubmed">29470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Health MDoP ALS 2007&#x2013;2011 data brief data brief: the Arego Paul Cellucci amyotrophic lateral sclerosis (ALS) registry of Massachusetts. 2016</Citation></Reference><Reference><Citation>Valle J, Roberts E, Paulukonis S, Collins N, English P, Kaye W. Epidemiology and surveillance of amyotrophic lateral sclerosis in two large metropolitan areas in California. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Jun;16((3&#x2013;4)):209&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544858</ArticleId><ArticleId IdType="pubmed">25822003</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chi&#xf2; A, Mitchell D, Swingler RJ, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010 Apr;81((4)):385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Ossher L, Bredin A, Kulka A, Pearce N, Talbot K, et al. Motor neuron disease register for England, Wales and Northern Ireland-an analysis of incidence in England. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Sep 17;:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32940088</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M. Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology. 2019;52((1&#x2013;2)):93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtman L, Jordan H, Wagner L, Horton DK, Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16((1&#x2013;2)):65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389704</ArticleId><ArticleId IdType="pubmed">25482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of amyotrophic lateral sclerosis: United States, 2012&#x2013;2013. MMWR Surveill Summ. 2016 Aug 5;65((8)):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490513</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri M, Cossu G, Saddi V, Simons EJ, Murgia D, Melis M, et al. Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics. 2011 Aug;12((3)):203&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158341</ArticleId><ArticleId IdType="pubmed">21667065</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundogdu B, Al-Lahham T, Kadlubar F, Spencer H, Rudnicki SA. Racial differences in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15((1&#x2013;2)):114&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264350</ArticleId><ArticleId IdType="pubmed">24067242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Heverin M, Vajda A, Crampsie A, Tobin K, Byrne S, et al. An exploratory spatial analysis of ALS incidence in Ireland over 17.5 years (1995-July 2013) PLoS One. 2014 May;9((5)):e96556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035264</ArticleId><ArticleId IdType="pubmed">24867594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, Stommel EW, Shi X, Torbick NM, Caller TA, Sabel CE, et al. Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland. Neurology. 2015 Nov;85((20)):1822&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">26574539</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Vajda A, Heverin M, Elamin M, Crampsie A, McLaughlin R, et al. Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland. Neurology. 2015 Apr;84((15)):1537&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25770197</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, Ruben P, van Eijk A, Peters SM, van Es MA, Horemans A, et al. Incidence, prevalence, and geographical clustering of motor neuron disease in the Netherlands. Neurology. 2021;96:e1227&#x2013;e1236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055340</ArticleId><ArticleId IdType="pubmed">33472922</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>